GLP-1 Drugs May Reduce Sexual Desire Through Serotonin — But Other Effects May Mask It | Research

The takeaway

GLP-1 agonists may decrease sexual desire through increased 5-HT2C serotonergic activity, but this effect is likely masked by competing positive influences including improved testosterone, vascular function, and mood.

Hidden effect
GLP-1 drugs may suppress sexual desire through serotonin, but this is masked by improvements in testosterone, blood flow, and mood

What the researchers found

GLP-1 agonism may decrease sexual desire via 5-HT2C serotonergic activation (analogous to SSRIs), but competing positive factors (testosterone increase, improved vasculature, mood) likely offset this effect in many patients.

Why it matters

Sexual desire is crucial to quality of life. Understanding that GLP-1 drugs have competing positive and negative effects on sexual function helps clinicians counsel patients appropriately.

How the study worked

Narrative review with targeted PubMed literature search, integrating evidence on GLP-1/serotonin interactions, sexual function, and a biopsychosocial framework analysis.

What this study cannot tell us

Entirely theoretical model. No direct measurement of 5-HT2C activation by GLP-1 drugs in humans. Biopsychosocial framework is speculative. No clinical trials measuring sexual desire as primary outcome.

How to read the evidence

Theoretical model with supporting indirect evidence. Hypothesis-generating rather than confirmatory.

When this study was published

Published in 2025.

The bigger picture

This reveals the complexity of GLP-1 drug effects on quality of life: simple metrics like weight and HbA1c miss important subjective outcomes like sexual desire.

Questions still open

Would 5-HT2C antagonists prevent GLP-1-induced sexual desire decrease?
Is the serotonergic effect dose-dependent?
Do different GLP-1 drugs affect 5-HT2C activity differently?

Common questions

Can GLP-1 drugs affect sexual desire?

They might. This review proposes that GLP-1 drugs could reduce sexual desire through the same serotonin pathway as antidepressants. However, weight loss, better hormones, and improved mood may counterbalance this, making the net effect hard to detect.

Should I worry about this on Ozempic?

For most patients, the positive effects (improved testosterone, better blood flow, enhanced body image) likely outweigh any serotonin-mediated desire reduction. But if you notice decreased sexual interest, discuss it with your doctor.

Read the original research

Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it.

Obesity pillars, 17, 100233

View on PubMed ↗Publisher’s paper ↗

Citation

Gelfand, Sonya T; Tveit, Meghan C; Simon, James A. (2026). Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it.. Obesity pillars, 17, 100233. https://doi.org/10.1016/j.obpill.2025.100233